Inside TIL therapy: daily hospital routines, caregiver support, chemo and infusion steps, and what recovery questions patients ask most. Interleukin-2 (IL-2) is often the most challenging part of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with bullous pemphigoid treated with IL-2 had ...

Anti-tumor activity of recombinant human Interleukin-21 (rIL-21): Preliminary data from a phase 2a study in patients with stage IV malignant melanoma (MM) without prior treatment No significant ...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...

Most patients with Sjogren's syndrome treated with low doses of interleukin-2 (IL-2) in a randomized, placebo-controlled trial showed significant improvement, researchers said. After 24 weeks in the ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced positive initial results from a first-in-human Phase 1 study (NCT05665062) of ...

Low dose interleukin 2 is being tested as an immunomodulatory approach in neurodegenerative diseases. It increases the number and activity of regulatory T cells (Tregs) that suppress inflammation. At ...

A Novel Anti-Apoptosis Gene: Re-expression of Survivin Messenger RNA as a Prognosis Marker in Non–Small-Cell Lung Cancers PURPOSE: To determine the short- and long-term efficacy and toxicity of the ...